Base de dados : MEDLINE
Pesquisa : G12.450.275 [Categoria DeCS]
Referências encontradas : 731 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 74 ir para página                         

  1 / 731 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29324805
[Au] Autor:Lee YT; Ko EJ; Lee Y; Kim KH; Kim MC; Lee YN; Kang SM
[Ad] Endereço:Center for Inflammation, Immunity & Infection, Institute for Biomedical Sciences, Georgia State University, Atlanta, Georgia, United States of America.
[Ti] Título:Intranasal vaccination with M2e5x virus-like particles induces humoral and cellular immune responses conferring cross-protection against heterosubtypic influenza viruses.
[So] Source:PLoS One;13(1):e0190868, 2018.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Current influenza vaccines do not provide broad cross-protection. Here, we report that intranasal vaccination with virus-like particles containing the highly conserved multiple ectodomains of matrix protein 2 (M2e5x VLP) of influenza virus induces broad cross-protection by M2-specific humoral and cellular immune responses. M2e5x VLP intranasal vaccination prevented severe weight loss, attenuated inflammatory cytokines and cellular infiltrates, and lowered viral loads, and induced germinal center phenotypic B and plasma cells. In addition, depletion studies demonstrate the protective roles of CD4 and CD8 T cells induced by M2e5x VLP intranasal vaccination. Thus, this study provides evidence that mucosal delivery of M2e5x VLP vaccine provides cross-protection by inducing humoral and cellular immune responses.
[Mh] Termos MeSH primário: Proteção Cruzada
Vírus da Influenza A Subtipo H3N2/imunologia
Vírus da Influenza A Subtipo H5N1/imunologia
Vacinas contra Influenza/administração & dosagem
Vacinas de Partículas Semelhantes a Vírus/administração & dosagem
Proteínas da Matriz Viral/imunologia
[Mh] Termos MeSH secundário: Administração Intranasal
Animais
Anticorpos Antivirais/análise
Anticorpos Antivirais/sangue
Linfócitos B/imunologia
Linfócitos T CD4-Positivos/imunologia
Linfócitos T CD8-Positivos/imunologia
Embrião de Galinha
Feminino
Pulmão/imunologia
Pulmão/virologia
Camundongos Endogâmicos BALB C
Infecções por Orthomyxoviridae/imunologia
Infecções por Orthomyxoviridae/prevenção & controle
Infecções por Orthomyxoviridae/virologia
Células Sf9
Spodoptera
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL
[Nm] Nome de substância:
0 (Antibodies, Viral); 0 (Influenza Vaccines); 0 (Vaccines, Virus-Like Particle); 0 (Viral Matrix Proteins)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180206
[Lr] Data última revisão:
180206
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180112
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0190868


  2 / 731 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27771184
[Au] Autor:van Straten M; Bardenstein S; Keningswald G; Banai M
[Ad] Endereço:"Hachaklait", Mutual Society for Veterinary Services, P.O.B. 3039, Caesarea Industrial Park, 38900, Israel. Electronic address: vanstraten@hachaklait.co.il.
[Ti] Título:Brucella abortus S19 vaccine protects dairy cattle against natural infection with Brucella melitensis.
[So] Source:Vaccine;34(48):5837-5839, 2016 11 21.
[Is] ISSN:1873-2518
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Brucellosis is a zoonotic disease that can cause severe illness in humans and considerable economic loss in the livestock industry. Although small ruminants are the preferential host for Brucella melitensis, this pathogen has emerged as a cause for Brucella outbreaks in cattle. S19 vaccination is implemented in many countries where B. abortus is endemic but its effectiveness against B. melitensis has not been validated. Here we show that vaccine effectiveness in preventing disease transmission between vaccinated and unvaccinated cohorts, as determined by seroconversion, was 87.2% (95% CI 69.5-94.6%). Furthermore, vaccination was associated with a reduced risk for abortion. Together, our data emphasize the role S19 vaccination could play in preventing B. melitensis outbreaks in areas where this pathogen is prevalent in small ruminant populations.
[Mh] Termos MeSH primário: Aborto Animal/prevenção & controle
Vacina contra Brucelose/administração & dosagem
Brucella melitensis/imunologia
Brucelose Bovina/prevenção & controle
[Mh] Termos MeSH secundário: Aborto Animal/microbiologia
Animais
Anticorpos Antibacterianos
Vacina contra Brucelose/imunologia
Brucella abortus/imunologia
Brucella melitensis/patogenicidade
Brucelose Bovina/transmissão
Bovinos
Proteção Cruzada
Feminino
Gravidez
Complicações Infecciosas na Gravidez/prevenção & controle
Complicações Infecciosas na Gravidez/veterinária
Soroconversão
Vacinação/veterinária
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antibodies, Bacterial); 0 (Brucella Vaccine)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:180206
[Lr] Data última revisão:
180206
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161025
[St] Status:MEDLINE


  3 / 731 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27771182
[Au] Autor:Yang L; Liu Y; Li S; Zhao H; Lin Q; Yu H; Huang X; Zheng Q; Cheng T; Xia N
[Ad] Endereço:State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Life Science & School of Public Health, Xiamen University, Xiamen, China.
[Ti] Título:A novel inactivated enterovirus 71 vaccine can elicit cross-protective immunity against coxsackievirus A16 in mice.
[So] Source:Vaccine;34(48):5938-5945, 2016 11 21.
[Is] ISSN:1873-2518
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Hand, foot, and mouth disease (HFMD) is a highly contagious disease that mainly affects infants and children. Enterovirus 71 (EV71) and coxsackievirus A16 (CA16) are the major pathogens of HFMD. Two EV71 vaccines were recently licensed in China and the administration of the EV71 vaccines is believed to significantly reduce the number of HFMD-related severe or fatal cases. However, a monovalent EV71 vaccine cannot cross-protect against CA16 infection, this may result in that it cannot effectively control the overall HFMD epidemic. In this study, a chimeric EV71, whose VP1/210-225 epitope was replaced by that of CA16, was constructed using a reverse genetics technique to produce a candidate EV71/CA16 bivalent vaccine strain. The chimeric EV71 was infectious and showed similar growth characteristics as its parental strain. The replacement of the VP1/210-225 epitope did not significantly affect the antigenicity and immunogenicity of EV71. More importantly, the chimeric EV71 could induce protective immunity against both EV71 and CA16, and protect neonatal mice against either EV71 or CA16 lethal infections, the chimeric EV71 constructed in this study was shown to be a feasible and promising candidate bivalent vaccine against both EV71 and CA16. The construction of a chimeric enterovirus also provides an alternative platform for broad-spectrum HFMD vaccines development.
[Mh] Termos MeSH primário: Infecções por Coxsackievirus/prevenção & controle
Proteção Cruzada
Infecções por Enterovirus/prevenção & controle
Enterovirus/imunologia
Vacinas Virais/imunologia
[Mh] Termos MeSH secundário: Animais
Anticorpos Neutralizantes/sangue
Anticorpos Antivirais/sangue
Infecções por Coxsackievirus/imunologia
Enterovirus Humano A/genética
Enterovirus Humano A/imunologia
Infecções por Enterovirus/imunologia
Epitopos/imunologia
Doença de Mão, Pé e Boca/prevenção & controle
Seres Humanos
Imunogenicidade da Vacina
Camundongos
Genética Reversa
Vacinas de Produtos Inativados/administração & dosagem
Vacinas de Produtos Inativados/imunologia
Vacinas Virais/administração & dosagem
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antibodies, Neutralizing); 0 (Antibodies, Viral); 0 (Epitopes); 0 (Vaccines, Inactivated); 0 (Viral Vaccines)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:180206
[Lr] Data última revisão:
180206
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161025
[St] Status:MEDLINE


  4 / 731 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28916870
[Au] Autor:Yuan X; Lin H; Li B; He K; Fan H
[Ad] Endereço:College of Veterinary Medicine, Nanjing Agricultural University, No. 1 Weigang, Nanjing, 210095, China.
[Ti] Título:Efficacy and immunogenicity of recombinant swinepox virus expressing the truncated S protein of a novel isolate of porcine epidemic diarrhea virus.
[So] Source:Arch Virol;162(12):3779-3789, 2017 Dec.
[Is] ISSN:1432-8798
[Cp] País de publicação:Austria
[La] Idioma:eng
[Ab] Resumo:Porcine epidemic diarrhea virus (PEDV) causes significant loss to the swine industry. The emergence of novel PEDV strains in recent years has decreased the effectiveness of PEDV vaccines. We have developed a live recombinant vaccine, a swinepox virus vector that expresses a truncated S protein (rSPV-St) from a recent PEDV strain, SQ2014, and evaluated its immunogenicity and effectiveness in a swine model. Vaccination of swine with rSPV-St elicited a robust antibody response specific for the homologous PEDV SQ2014. Serum IgA titers in rSPV-St-vaccinated animals were significantly higher than in those immunized with inactivated vaccines. The effectiveness of antibodies induced by the rSPV-St vaccine in protection against PEDV was tested in a passive-transfer model in which piglets were challenged with the homologous virus SQ2014 and the heterologous strain CV777. When challenged with the homologous virus, sera from rSPV-St vaccination provided complete protection. However, sera from rSPV-St vaccination did not provide any protection against the heterologous virus challenge. Amino acid sequence differences in the S proteins of the two viruses were identified within neutralizing epitopes, which might have contributed to the divergent clinical results. Our data suggest that rSPV-St is potentially an effective vaccine against infection with emerging PEDV strains.
[Mh] Termos MeSH primário: Infecções por Coronavirus/veterinária
Portadores de Fármacos
Vírus da Diarreia Epidêmica Suína/imunologia
Glicoproteína da Espícula de Coronavírus/imunologia
Suipoxvirus/genética
Doenças dos Suínos/prevenção & controle
Vacinas Virais/imunologia
[Mh] Termos MeSH secundário: Animais
Anticorpos Antivirais/sangue
Infecções por Coronavirus/prevenção & controle
Proteção Cruzada
Imunização Passiva
Imunoglobulina A/sangue
Vírus da Diarreia Epidêmica Suína/genética
Proteínas Recombinantes/genética
Proteínas Recombinantes/imunologia
Glicoproteína da Espícula de Coronavírus/genética
Suínos
Resultado do Tratamento
Vacinas Atenuadas/administração & dosagem
Vacinas Atenuadas/genética
Vacinas Atenuadas/imunologia
Vacinas Sintéticas/administração & dosagem
Vacinas Sintéticas/genética
Vacinas Sintéticas/imunologia
Vacinas Virais/administração & dosagem
Vacinas Virais/genética
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antibodies, Viral); 0 (Drug Carriers); 0 (Immunoglobulin A); 0 (Recombinant Proteins); 0 (Spike Glycoprotein, Coronavirus); 0 (Vaccines, Attenuated); 0 (Vaccines, Synthetic); 0 (Viral Vaccines)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171113
[Lr] Data última revisão:
171113
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170917
[St] Status:MEDLINE
[do] DOI:10.1007/s00705-017-3548-1


  5 / 731 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28887040
[Au] Autor:Kim YJ; Ko EJ; Kim MC; Lee YN; Kim KH; Jung YJ; Kang SM
[Ad] Endereço:Center for Inflammation, Immunity & Infection, Institute for Biomedical Sciences, Georgia State University, Atlanta, GA 30303, USA.
[Ti] Título:Roles of antibodies to influenza A virus hemagglutinin, neuraminidase, and M2e in conferring cross protection.
[So] Source:Biochem Biophys Res Commun;493(1):393-398, 2017 Nov 04.
[Is] ISSN:1090-2104
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Although neuraminidase (NA) is the second major viral glycoprotein of influenza virus, its immune mechanism as a vaccine target has been less considered. Here we compared the properties of antibodies and the efficacy of cross protection by N1 and N2 NA proteins, inactivated split influenza vaccines (split), and tandem repeat extracellular domain M2 on virus-like particles (M2e5x VLP). Anti-NA immune sera could confer better cross-protection against multiple heterologous influenza viruses correlating with NA inhibition activity compared to split vaccine immune sera. Whereas split vaccine was superior to NA in conferring homologous protection. NA and M2e immune sera each showed comparable survival protection. Protective efficacy by NA immune sera was lower in Fc receptor common γ-chain deficient mice but comparable in C3 complement deficient mice compared to that in wild type mice, suggesting a role of Fc receptor in NA immunity.
[Mh] Termos MeSH primário: Anticorpos/imunologia
Proteção Cruzada/imunologia
Vírus da Influenza A/imunologia
Vacinas contra Influenza/imunologia
Influenza Humana/imunologia
Neuraminidase/imunologia
[Mh] Termos MeSH secundário: Animais
Feminino
Glicoproteínas de Hemaglutininação de Vírus da Influenza/imunologia
Seres Humanos
Vacinas contra Influenza/administração & dosagem
Influenza Humana/prevenção & controle
Influenza Humana/virologia
Masculino
Camundongos
Camundongos Endogâmicos BALB C
Camundongos Transgênicos
Taxa de Sobrevida
Resultado do Tratamento
Proteínas da Matriz Viral
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antibodies); 0 (Hemagglutinin Glycoproteins, Influenza Virus); 0 (Influenza Vaccines); 0 (M2 protein, Influenza A virus); 0 (Viral Matrix Proteins); 0 (hemagglutinin, avian influenza A virus); EC 3.2.1.18 (Neuraminidase)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171023
[Lr] Data última revisão:
171023
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170910
[St] Status:MEDLINE


  6 / 731 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28859431
[Au] Autor:Baussano I; Lazzarato F; Ronco G; Lehtinen M; Dillner J; Franceschi S
[Ad] Endereço:International Agency for Research on Cancer, Lyon, France.
[Ti] Título:Different Challenges in Eliminating HPV16 Compared to Other Types: A Modeling Study.
[So] Source:J Infect Dis;216(3):336-344, 2017 Aug 01.
[Is] ISSN:1537-6613
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Background: Human papillomavirus (HPV) vaccination is still not reaching many high-risk populations. HPV16/18 vaccines offer cross-protection against other types, for example, HPV45. Both direct vaccine efficacy and indirect herd protection contribute to vaccination effectiveness. Methods: We used a dynamic transmission model, calibrated to cervical screening data from Italy, to estimate vaccination effectiveness against HPV16 and HPV45 infection, assuming for HPV45 either 95% or lower cross-protection. Results: Basic reproductive number was smaller (2.1 vs 4.0) and hence vaccine effectiveness and herd protection stronger for HPV45 than for HPV16. The largest difference in the reduction of infection prevalence in women <35 years old was found at 70% coverage in girls-only vaccination programs (99% vs 83% for total protection for HPV45 and HPV16, respectively, mainly owing to stronger herd protection, ie, 37% vs 16%). In gender-neutral vaccination, the largest difference was at 40% coverage (herd protection, 54% vs 28% for HPV16 and HPV45, respectively). With ≥80% coverage, even 50% cross-protection would reduce HPV45 by ≥94%. Conclusions: The characteristics of individual high-risk HPV types strongly influence herd protection and determine the level of coverage and cross-protection required to reduce or eliminate the infection through HPV vaccination. HPV16 infection and related cancers are the most difficult to eliminate.
[Mh] Termos MeSH primário: Papillomavirus Humano 16
Papillomavirus Humano 18
Infecções por Papillomavirus/prevenção & controle
Vacinas contra Papillomavirus/administração & dosagem
Neoplasias do Colo do Útero/prevenção & controle
[Mh] Termos MeSH secundário: Adolescente
Adulto
Idoso
Criança
Proteção Cruzada/imunologia
Feminino
Seres Humanos
Imunidade Coletiva/imunologia
Programas de Imunização
Itália
Masculino
Meia-Idade
Modelos Teóricos
Neoplasias do Colo do Útero/virologia
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Papillomavirus Vaccines)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170907
[Lr] Data última revisão:
170907
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170902
[St] Status:MEDLINE
[do] DOI:10.1093/infdis/jix299


  7 / 731 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28727722
[Au] Autor:Mitobe J; Sinha R; Mitra S; Nag D; Saito N; Shimuta K; Koizumi N; Koley H
[Ad] Endereço:Department of Bacteriology I, National Institute of Infectious Diseases, Shinjuku, Tokyo, Japan.
[Ti] Título:An attenuated Shigella mutant lacking the RNA-binding protein Hfq provides cross-protection against Shigella strains of broad serotype.
[So] Source:PLoS Negl Trop Dis;11(7):e0005728, 2017 Jul.
[Is] ISSN:1935-2735
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Few live attenuated vaccines protect against multiple serotypes of bacterial pathogen because host serotype-specific immune responses are limited to the serotype present in the vaccine strain. Here, immunization with a mutant of Shigella flexneri 2a protected guinea pigs against subsequent infection by S. dysenteriae type 1 and S. sonnei strains. This deletion mutant lacked the RNA-binding protein Hfq leading to increased expression of the type III secretion system via loss of regulation, resulting in attenuation of cell viability through repression of stress response sigma factors. Such increased antigen production and simultaneous attenuation were expected to elicit protective immunity against Shigella strains of heterologous serotypes. Thus, the vaccine potential of this mutant was tested in two guinea pig models of shigellosis. Animals vaccinated in the left eye showed fewer symptoms upon subsequent challenge via the right eye, and even survived subsequent intestinal challenge. In addition, oral vaccination effectively induced production of immunoglobulins without severe side effects, again protecting all animals against subsequent intestinal challenge with S. dysenteriae type 1 or S. sonnei strains. Antibodies against common virulence proteins and the O-antigen of S. flexneri 2a were detected by immunofluorescence microscopy. Reaction of antibodies with various strains, including enteroinvasive Escherichia coli, suggested that common virulence proteins induced protective immunity against a range of serotypes. Therefore, vaccination is expected to cover not only the most prevalent serotypes of S. sonnei and S. flexneri 2a, but also various Shigella strains, including S. dysenteriae type 1, which produces Shiga toxin.
[Mh] Termos MeSH primário: Proteção Cruzada
Disenteria Bacilar/prevenção & controle
Deleção de Genes
Fator Proteico 1 do Hospedeiro/deficiência
Vacinas contra Shigella/imunologia
Shigella/genética
Shigella/imunologia
[Mh] Termos MeSH secundário: Animais
Modelos Animais de Doenças
Disenteria Bacilar/imunologia
Disenteria Bacilar/patologia
Cobaias
Masculino
Viabilidade Microbiana
Sorogrupo
Vacinas contra Shigella/administração & dosagem
Vacinas contra Shigella/genética
Análise de Sobrevida
Vacinas Atenuadas/administração & dosagem
Vacinas Atenuadas/genética
Vacinas Atenuadas/imunologia
Virulência
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Host Factor 1 Protein); 0 (Shigella Vaccines); 0 (Vaccines, Attenuated)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170814
[Lr] Data última revisão:
170814
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170721
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pntd.0005728


  8 / 731 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28717032
[Au] Autor:Kuipers K; Jong WSP; van der Gaast-de Jongh CE; Houben D; van Opzeeland F; Simonetti E; van Selm S; de Groot R; Koenders MI; Azarian T; Pupo E; van der Ley P; Langereis JD; Zomer A; Luirink J; de Jonge MI
[Ad] Endereço:Laboratory of Pediatric Infectious Diseases, Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, The Netherlands.
[Ti] Título:Th17-Mediated Cross Protection against Pneumococcal Carriage by Vaccination with a Variable Antigen.
[So] Source:Infect Immun;85(10), 2017 Oct.
[Is] ISSN:1098-5522
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Serotype-specific protection against is an important limitation of the current polysaccharide-based vaccines. To prevent serotype replacement, reduce transmission, and limit the emergence of new variants, it is essential to induce broad protection and restrict pneumococcal colonization. In this study, we used a prototype vaccine formulation consisting of lipopolysaccharide (LPS)-detoxified outer membrane vesicles (OMVs) from serovar Typhimurium displaying the variable N terminus of PspA (α1α2) for intranasal vaccination, which induced strong Th17 immunity associated with a substantial reduction of pneumococcal colonization. Despite the variable nature of this protein, a common major histocompatibility complex class (MHC-II) epitope was identified, based on prediction combined with screening, and was essential for interleukin-17 A (IL-17A)-mediated cross-reactivity and associated with cross protection. Based on 1,352 PspA sequences derived from a pneumococcal carriage cohort, this OMV-based vaccine formulation containing a single α1α2 type was estimated to cover 19.1% of strains, illustrating the potential of Th17-mediated cross protection.
[Mh] Termos MeSH primário: Proteção Cruzada
Interleucina-17/imunologia
Infecções Pneumocócicas/prevenção & controle
Vacinas Pneumocócicas/imunologia
Salmonella typhimurium/química
Streptococcus pneumoniae/imunologia
Células Th17/imunologia
[Mh] Termos MeSH secundário: Administração Intranasal
Animais
Antígenos de Bactérias/imunologia
Antígenos de Bactérias/isolamento & purificação
Proteínas da Membrana Bacteriana Externa/imunologia
Proteínas de Bactérias/genética
Proteínas de Bactérias/imunologia
Simulação por Computador
Epitopos/química
Epitopos/genética
Epitopos/imunologia
Epitopos/isolamento & purificação
Genes MHC Classe II
Proteínas de Choque Térmico/genética
Proteínas de Choque Térmico/imunologia
Interleucina-17/biossíntese
Lipopolissacarídeos/imunologia
Camundongos
Infecções Pneumocócicas/imunologia
Vacinas Pneumocócicas/química
Salmonella typhimurium/imunologia
Vesículas Secretórias/química
Vesículas Secretórias/imunologia
Vacinação
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antigens, Bacterial); 0 (Bacterial Outer Membrane Proteins); 0 (Bacterial Proteins); 0 (Epitopes); 0 (Heat-Shock Proteins); 0 (Interleukin-17); 0 (Lipopolysaccharides); 0 (Pneumococcal Vaccines); 0 (phage shock protein, Bacteria)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171017
[Lr] Data última revisão:
171017
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170719
[St] Status:MEDLINE


  9 / 731 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28696188
[Au] Autor:Makhdoomi MA; Khan L; Kumar S; Aggarwal H; Singh R; Lodha R; Singla M; Das BK; Kabra SK; Luthra K
[Ad] Endereço:1​Department of Biochemistry, All India Institute of Medical Sciences, New Delhi 110029, India.
[Ti] Título:Evolution of cross-neutralizing antibodies and mapping epitope specificity in plasma of chronic HIV-1-infected antiretroviral therapy-naïve children from India.
[So] Source:J Gen Virol;98(7):1879-1891, 2017 Jul.
[Is] ISSN:1465-2099
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Delineating the factors leading to the development of broadly neutralizing antibodies (bnAbs) during natural HIV-1 infection and dissecting their epitope specificities generates useful information for vaccine design. This is the first longitudinal study to assess the plasma-neutralizing antibody response and neutralizing determinants in HIV-1-infected children from India. We enrolled 26 and followed up 20 antiretroviral therapy (ART)-naïve, asymptomatic, chronic HIV-1-infected children. Five (19.2 %) baseline and 10 (50 %) follow-up plasma samples neutralized ≥50 % of subtypes A, B and C tier 2 viruses at an ID50 titre ≥150. A modest improvement in neutralization breadth and potency was observed with time. At baseline, subtype C-specific neutralization predominated (P=0.026); interestingly, follow-up samples exhibited cross-neutralizing activity. Epitope mapping revealed V3C reactive antibodies with significantly increased Max50 binding titres in follow-up samples from five infected children; patient #4's plasma antibodies exhibited V3-directed neutralization. A salient observation was the presence of CD4 binding site (CD4bs)-specific NAbs in patient #18 that improved with time (1.76-fold). The RSC3 wild-type (RSC3WT) protein-depleted plasma eluate of patient #18 demonstrated a more than 50% ID50 decrease in neutralization capacity against five HIV-1 pseudoviruses. Further, the presence of CD4bs-neutralizing determinants in patient #18's plasma was confirmed by the neutralizing activity demonstrated by the CD4bs-directed IgG fraction purified from this plasma, and competition with sCD4 against JRFLgp120, identifying this paediatric donor as a potential candidate for the isolation of CD4bs-directed bnAbs. Overall, we observed a relative increase in plasma-neutralizing activity with time in HIV-1-infected children, which suggests that the bnAbs evolve.
[Mh] Termos MeSH primário: Anticorpos Neutralizantes/sangue
Anticorpos Antivirais/sangue
Proteção Cruzada/imunologia
Epitopos/imunologia
Anticorpos Anti-HIV/sangue
HIV-1/classificação
HIV-1/imunologia
[Mh] Termos MeSH secundário: Adolescente
Anticorpos Neutralizantes/imunologia
Anticorpos Antivirais/imunologia
Contagem de Linfócito CD4
Criança
Pré-Escolar
Mapeamento de Epitopos
Feminino
Anticorpos Anti-HIV/imunologia
Proteína gp120 do Envelope de HIV/imunologia
Infecções por HIV/imunologia
Infecções por HIV/virologia
Seres Humanos
Imunoglobulina G/sangue
Imunoglobulina G/imunologia
Índia
Estudos Longitudinais
Masculino
Fragmentos de Peptídeos/imunologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antibodies, Neutralizing); 0 (Antibodies, Viral); 0 (Epitopes); 0 (HIV Antibodies); 0 (HIV Envelope Protein gp120); 0 (HIV envelope protein gp120 (305-321)); 0 (Immunoglobulin G); 0 (Peptide Fragments)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170804
[Lr] Data última revisão:
170804
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170712
[St] Status:MEDLINE
[do] DOI:10.1099/jgv.0.000824


  10 / 731 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28691894
[Au] Autor:Cano-Gómez C; Fernández-Pinero J; García-Casado MA; Zell R; Jiménez-Clavero MA
[Ad] Endereço:1​Centro de Investigación en Sanidad Animal (CISA)-INIA, Ctra Algete-El Casar s/n, 28130 Valdeolmos, Spain.
[Ti] Título:Characterization of PTV-12, a newly described porcine teschovirus serotype: in vivo infection and cross-protection studies.
[So] Source:J Gen Virol;98(7):1636-1645, 2017 Jul.
[Is] ISSN:1465-2099
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Porcine teschoviruses (PTVs) constitute 1 of the 31 genera within the Picornaviridae family, comprising at least 13 genetic types (PTV-1 to PTV-13), of which only 11 (PTV-1 to PTV-11) have been recognized as serotypes to date. Specific for swine and wild boars, most PTVs are usually non-pathogenic, but some viral variants cause severe disorders in the central nervous system (Teschen disease) or milder signs (Talfan disease), as well as reproductive, digestive and respiratory disorders and skin lesions. Previous studies revealed a high diversity of teschoviruses circulating in Spanish pig populations. Phylogenetic analysis performed with these sequences and others available in GenBank disclosed 13 clusters, 11 of which corresponded to the known PTV serotypes, and 1 of 2 additional groups is represented by isolate CC25, whose full-length genomic sequence has been obtained. This group is new to science, and was putatively named PTV-12. Here, a complete characterization of this isolate is presented, including the experimental infection of minipigs to assess tissue tropism and possible pathogenicity in vivo in the host species. In addition, using this experimental animal model, we investigated whether a pre-existing infection with this PTV-12 isolate could confer cross-protection against infection with a heterotypic PTV-1 virulent strain. Based on phylogenetic analysis and serological data, we propose CC25 as the prototype strain of a new teschovirus serotype, PTV-12.
[Mh] Termos MeSH primário: Proteção Cruzada/imunologia
Infecções por Picornaviridae/imunologia
Doenças dos Suínos/imunologia
Porco Miniatura/virologia
Teschovirus/classificação
Teschovirus/imunologia
Tropismo Viral/fisiologia
[Mh] Termos MeSH secundário: Animais
Anticorpos Neutralizantes/sangue
Anticorpos Antivirais/sangue
Infecções por Picornaviridae/virologia
Sorogrupo
Sorotipagem
Espanha
Suínos
Doenças dos Suínos/virologia
Teschovirus/genética
Teschovirus/isolamento & purificação
Viremia/virologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antibodies, Neutralizing); 0 (Antibodies, Viral)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170804
[Lr] Data última revisão:
170804
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170711
[St] Status:MEDLINE
[do] DOI:10.1099/jgv.0.000822



página 1 de 74 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde